News Release

How NORE1A acts as a barrier to tumor growth

Peer-Reviewed Publication

Rockefeller University Press

Ras-induced Senescence

image: Activated Ras induces cell senescence (blue) are shown in the presence (left), but not the absence (right), of NORE1A. view more 

Credit: Clark Lab

Researchers reveal how cells protect themselves from a protein that is a key driver of cancer. The study appears in The Journal of Cell Biology.

Mutations that activate a protein called Ras drive excessive cell proliferation associated with cancer, but their ability to promote tumor growth is limited by the fact that they also induce cells to exit the cell cycle and become dormant, or senescent. How active Ras mutants induce senescence, and how this pathway is disrupted in cancer cells is still unclear.

Geoffrey Clark and colleagues from the University of Louisville examined the role of the tumor suppressor NORE1A, a protein that binds to active Ras. Overexpressing NORE1A induced cell senescence, whereas removing the protein prevented senescence and enhanced the transformation of cells with cancer-promoting Ras mutations.

The researchers found that Ras enhanced NORE1A's association with a kinase called HIPK2, and that this interaction was required for cell senescence. NORE1A promoted HIPK2's association with p53, a tumor suppressor that plays a major role in restricting cancer development. HIPK2 is known to modify p53 in ways that cause either apoptosis, a kind of cell suicide, or senescence. Clark and colleagues found that NORE1A enhanced the senescence pathway.

The findings delineate how NORE1A allows Ras to modulate p53 function and induce cell senescence, and the loss of NORE1A may be a critical step in the growth of tumors.

###

Donninger, H., et al. 2015. J. Cell Biol. doi:10.1083/jcb.201408087

About The Journal of Cell Biology

The Journal of Cell Biology (JCB) is published by The Rockefeller University Press. All editorial decisions on manuscripts submitted are made by active scientists in conjunction with our in-house scientific editors. JCB content is posted to PubMed Central, where it is available to the public for free six months after publication. Authors retain copyright of their published works, and third parties may reuse the content for non-commercial purposes under a creative commons license. For more information, please visit http://www.jcb.org.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.